Forschungsdatenbank PMU-SQQUID

Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles.
Binder, HM; Maeding, N; Wolf, M; Cronemberger Andrade, A; Vari, B; Krisch, L; Gomes, FG; Blöchl, C; Muigg, K; Poupardin, R; Raninger, AM; Heuser, T; Obermayer, A; Ebner-Peking, P; Pleyer, L; Greil, R; Huber, CG; Schallmoser, K; Strunk, D;
Cells. 2021; 10(12):
Originalarbeiten (Zeitschrift)

Abstract/Keywords Web of Science PubMed PUBMED Central Full Text

PMU-Autor/inn/en

Binder Heide-Marie
Cronemberger Andrade André
Ebner Patricia
Greil Richard
Gueths Gomes Fausto
Krisch Linda
Maeding Nicole
Muigg Katharina
Pleyer Lisa
Poupardin Rodolphe
Raninger Anna
Schallmoser Katharina
Strunk Dirk
Vári Balázs
Wolf Martin

Abstract

100x using tangential flow filtration (TFF) and separated AML-derived soluble factors and cells in parallel. EVs were characterized by electron microscopy, immunoblotting, and flow cytometry, confirming the double-membrane morphology, purity and identity. AML-EVs showed significant enrichment of immune response and leukemia-related pathways in tandem mass-tag proteomics and a significant dose-dependent inhibition of T cell proliferation, which was not observed with AML cells or their soluble factors. Furthermore, AML-EVs dose-dependently reduced NK cell lysis of third-party K-562 leukemia targets. This emphasizes the peculiar role of AML-EVs in leukemia immune escape and indicates novel EV-based targets for therapeutic interventions.

Find related publications in this database (Keywords)

acute myeloid leukemia (AML)
extracellular vesicles (EV)
immunomodulation
MISEV